GALT
Galectin Therapeutics Inc.
Biotechnology
Market Cap$135M
5Y Perf.-23.6%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
GALT vs ELVN vs IMVT vs NUVL vs CRL
Revenue, margins, valuation, and 5-year total return — side by side.
ELVN
Enliven Therapeutics, Inc.
Biotechnology
Market Cap$2.42B
5Y Perf.+89.0%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.88B
5Y Perf.+176.7%
NUVL
Nuvalent, Inc.
Biotechnology
Market Cap$7.74B
5Y Perf.+476.9%
CRL
Charles River Laboratories International, Inc.
Medical - Diagnostics & Research
Market Cap$8.76B
5Y Perf.-56.4%
GALT vs ELVN vs IMVT vs NUVL vs CRL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GALT | ELVN | IMVT | NUVL | CRL |
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $135M | $2.42B | $5.88B | $7.74B | $8.76B |
| Revenue (TTM) | $0.00 | $0.00 | $0.00 | $0.00 | $4.03B |
| Net Income (TTM) | $-37M | $-104M | $-464M | $-450M | $-185M |
| Gross Margin | — | — | — | — | 31.9% |
| Operating Margin | — | — | — | — | 11.8% |
| Forward P/E | — | — | — | — | 16.0x |
| Total Debt | $106M | $0.00 | $98K | $0.00 | $3.07B |
| Cash & Equiv. | $15M | $99M | $714M | $262M | $214M |
GALT vs ELVN vs IMVT vs NUVL vs CRL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GALT
ELVN
IMVT
NUVL
CRL
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Galectin Therapeuti… (GALT) | 100 | 76.4 | -23.6% |
| Enliven Therapeutic… (ELVN) | 100 | 189.0 | +89.0% |
| Immunovant, Inc. (IMVT) | 100 | 276.7 | +176.7% |
| Nuvalent, Inc. (NUVL) | 100 | 576.9 | +476.9% |
| Charles River Labor… (CRL) | 100 | 43.6 | -56.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GALT vs ELVN vs IMVT vs NUVL vs CRL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: GALT and ELVN are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Enliven Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. CRL also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
GALT
Galectin Therapeutics Inc.
The Income Pick
GALT carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 0 yrs, beta 0.66, yield 0.1%
- Beta 0.66 vs CRL's 1.44
- 0.1% yield; the other 4 pay no meaningful dividend
Best for: income & stability
ELVN
Enliven Therapeutics, Inc.
The Growth Play
ELVN is the #2 pick in this set and the best alternative if growth exposure is your priority.
- EPS growth 3.2%
- 3.4% margin vs GALT's -29.7%
- +118.7% vs CRL's +25.7%
Best for: growth exposure
IMVT
Immunovant, Inc.
The Defensive Pick
IMVT is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.36, Low D/E 0.0%, current ratio 11.16x
Best for: sleep-well-at-night
NUVL
Nuvalent, Inc.
The Long-Run Compounder
NUVL is the clearest fit if your priority is long-term compounding and defensive.
- 461.5% 10Y total return vs IMVT's 190.9%
- Beta 1.01, current ratio 15.27x
Best for: long-term compounding and defensive
CRL
Charles River Laboratories International, Inc.
The Growth Leader
CRL ranks third and is worth considering specifically for growth and efficiency.
- -0.9% revenue growth vs GALT's -59.9%
- -2.5% ROA vs GALT's -290.0%
Best for: growth and efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CRL | -0.9% revenue growth vs GALT's -59.9% |
| Quality / Margins | ELVN | 3.4% margin vs GALT's -29.7% |
| Stability / Safety | GALT | Beta 0.66 vs CRL's 1.44 |
| Dividends | GALT | 0.1% yield; the other 4 pay no meaningful dividend |
| Momentum (1Y) | ELVN | +118.7% vs CRL's +25.7% |
| Efficiency (ROA) | CRL | -2.5% ROA vs GALT's -290.0% |
GALT vs ELVN vs IMVT vs NUVL vs CRL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
FY 2025
GALT vs ELVN vs IMVT vs NUVL vs CRL — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCRLLAGGINGIMVT
Who Leads Where
CRL leads in 3 of 6 categories
GALT leads 1 • NUVL leads 1 • ELVN leads 0 • IMVT leads 0 • 1 tied
Explore the data ↓IMVTImmunovant, Inc.
0leads
ELVNEnliven Therapeutics,…
0leads
NUVLNuvalent, Inc.
1leads
GALTGalectin Therapeutics…
1leads
CRLCharles River Laborat…
3leads
6 Total Categories
CATEGORYLEADERvs GALTvs NUVLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
GALT1/1
Valuation MetricsMultiples, price ratios, and targets
CRL2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CRL6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NUVL4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
CRL1/1
Income & Cash Flow (Last 12 Months)
GALT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CRL and NUVL operate at a comparable scale, with $4.0B and $0 in trailing revenue.
| Metric | GALTGalectin Therapeu… | ELVNEnliven Therapeut… | IMVTImmunovant, Inc. | NUVLNuvalent, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $0 | $0 | $4.0B |
| EBITDAEarnings before interest/tax | -$31M | -$119M | -$487M | -$346M | $824M |
| Net IncomeAfter-tax profit | -$37M | -$104M | -$464M | -$450M | -$185M |
| Free Cash FlowCash after capex | -$31M | -$70M | -$423M | -$313M | $391M |
| Gross MarginGross profit ÷ Revenue | — | — | — | — | +31.9% |
| Operating MarginEBIT ÷ Revenue | — | — | — | — | +11.8% |
| Net MarginNet income ÷ Revenue | — | — | — | — | -4.6% |
| FCF MarginFCF ÷ Revenue | — | — | — | — | +9.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — | +1.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +27.8% | +2.2% | +19.7% | -17.8% | -160.0% |
GALT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
CRL leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | GALTGalectin Therapeu… | ELVNEnliven Therapeut… | IMVTImmunovant, Inc. | NUVLNuvalent, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| Market CapShares × price | $135M | $2.4B | $5.9B | $7.7B | $8.8B |
| Enterprise ValueMkt cap + debt − cash | $227M | $2.3B | $5.2B | $7.5B | $11.6B |
| Trailing P/EPrice ÷ TTM EPS | -2.76x | -22.27x | -10.60x | -18.00x | -61.04x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | 16.00x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | 12.75x |
| Price / SalesMarket cap ÷ Revenue | — | — | — | — | 2.18x |
| Price / BookPrice ÷ Book value/share | — | 5.02x | 6.20x | 6.13x | 2.74x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 16.90x |
CRL leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
CRL leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
CRL delivers a -5.7% return on equity — every $100 of shareholder capital generates $-6 in annual profit, vs $-47 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRL's 0.95x. On the Piotroski fundamental quality scale (0–9), CRL scores 4/9 vs NUVL's 1/9, reflecting mixed financial health.
| Metric | GALTGalectin Therapeu… | ELVNEnliven Therapeut… | IMVTImmunovant, Inc. | NUVLNuvalent, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -24.2% | -47.1% | -42.8% | -5.7% |
| ROA (TTM)Return on assets | -2.9% | -23.4% | -44.1% | -37.8% | -2.5% |
| ROICReturn on invested capital | — | -32.8% | — | -32.5% | +6.3% |
| ROCEReturn on capital employed | — | -31.1% | -66.1% | -34.4% | +8.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 | 2 | 1 | 4 |
| Debt / EquityFinancial leverage | — | — | 0.00x | — | 0.95x |
| Net DebtTotal debt minus cash | $91M | -$99M | -$714M | -$262M | $2.9B |
| Cash & Equiv.Liquid assets | $15M | $99M | $714M | $262M | $214M |
| Total DebtShort + long-term debt | $106M | $0 | $98,000 | $0 | $3.1B |
| Interest CoverageEBIT ÷ Interest expense | -4.24x | — | — | -26.85x | 4.29x |
CRL leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NUVL leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NUVL five years ago would be worth $56,149 today (with dividends reinvested), compared to $5,336 for CRL. Over the past 12 months, ELVN leads with a +118.7% total return vs CRL's +25.7%. The 3-year compound annual growth rate (CAGR) favors NUVL at 40.7% vs CRL's -2.2% — a key indicator of consistent wealth creation.
| Metric | GALTGalectin Therapeu… | ELVNEnliven Therapeut… | IMVTImmunovant, Inc. | NUVLNuvalent, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -48.1% | +162.2% | +11.7% | +4.4% | -12.3% |
| 1-Year ReturnPast 12 months | +50.0% | +118.7% | +102.4% | +47.0% | +25.7% |
| 3-Year ReturnCumulative with dividends | +11.7% | +112.9% | +49.8% | +178.8% | -6.5% |
| 5-Year ReturnCumulative with dividends | -44.6% | +46.6% | +84.4% | +461.5% | -46.6% |
| 10-Year ReturnCumulative with dividends | +66.7% | -32.1% | +190.9% | +461.5% | +114.0% |
| CAGR (3Y)Annualised 3-year return | +3.8% | +28.6% | +14.4% | +40.7% | -2.2% |
NUVL leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — GALT and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
GALT is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than CRL's 1.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 96.2% from its 52-week high vs GALT's 29.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GALTGalectin Therapeu… | ELVNEnliven Therapeut… | IMVTImmunovant, Inc. | NUVLNuvalent, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.66x | 1.23x | 1.36x | 1.01x | 1.44x |
| 52-Week HighHighest price in past year | $7.13 | $48.50 | $30.09 | $113.02 | $228.88 |
| 52-Week LowLowest price in past year | $1.21 | $14.79 | $13.36 | $63.56 | $132.58 |
| % of 52W HighCurrent price vs 52-week peak | +29.5% | +84.0% | +96.2% | +93.2% | +77.6% |
| RSI (14)Momentum oscillator 0–100 | 37.1 | 46.3 | 50.6 | 48.9 | 57.4 |
| Avg Volume (50D)Average daily shares traded | 345K | 1.1M | 1.4M | 546K | 792K |
Evenly matched — GALT and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
CRL leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: GALT as "Buy", ELVN as "Buy", IMVT as "Buy", NUVL as "Buy", CRL as "Buy". Consensus price targets imply 423.8% upside for GALT (target: $11) vs 16.2% for CRL (target: $206).
| Metric | GALTGalectin Therapeu… | ELVNEnliven Therapeut… | IMVTImmunovant, Inc. | NUVLNuvalent, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $11.00 | $59.00 | $45.50 | $144.40 | $206.43 |
| # AnalystsCovering analysts | 11 | 6 | 23 | 14 | 36 |
| Dividend YieldAnnual dividend ÷ price | +0.1% | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | — | 1 |
| Dividend / ShareAnnual DPS | $0.00 | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.0% | 0.0% | 0.0% | +4.1% |
CRL leads this category, winning 1 of 1 comparable metric.
Key Takeaway
CRL leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). GALT leads in 1 (Income & Cash Flow). 1 tied.
Best OverallCharles River Laboratories … (CRL)Leads 3 of 6 categories
Loading custom metrics...
GALT vs ELVN vs IMVT vs NUVL vs CRL: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is GALT or ELVN or IMVT or NUVL or CRL a better buy right now?
Analysts rate Galectin Therapeutics Inc.
(GALT) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — GALT or ELVN or IMVT or NUVL or CRL?
Over the past 5 years, Nuvalent, Inc.
(NUVL) delivered a total return of +461. 5%, compared to -46. 6% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: NUVL returned +461. 5% versus ELVN's -32. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — GALT or ELVN or IMVT or NUVL or CRL?
By beta (market sensitivity over 5 years), Galectin Therapeutics Inc.
(GALT) is the lower-risk stock at 0. 66β versus Charles River Laboratories International, Inc. 's 1. 44β — meaning CRL is approximately 119% more volatile than GALT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — GALT or ELVN or IMVT or NUVL or CRL?
On earnings-per-share growth, the picture is similar: Enliven Therapeutics, Inc.
grew EPS 3. 2% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — GALT or ELVN or IMVT or NUVL or CRL?
Galectin Therapeutics Inc.
(GALT) is the more profitable company, earning 0. 0% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRL leads at 12. 6% versus 0. 0% for NUVL. At the gross margin level — before operating expenses — CRL leads at 30. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is GALT or ELVN or IMVT or NUVL or CRL more undervalued right now?
Analyst consensus price targets imply the most upside for GALT: 423.
8% to $11. 00.
07Which pays a better dividend — GALT or ELVN or IMVT or NUVL or CRL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is GALT or ELVN or IMVT or NUVL or CRL better for a retirement portfolio?
For long-horizon retirement investors, Galectin Therapeutics Inc.
(GALT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66)). Both have compounded well over 10 years (GALT: +66. 7%, CRL: +114. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between GALT and ELVN and IMVT and NUVL and CRL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.